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Abstract
Bisphenol-A (BPA) is one of the most widespread EDCs used as a base compound in the manufacture of polycarbonate
plastics. The aim of our research has been to study how the exposure to BPA during pregnancy affects weight, glucose
homeostasis, pancreatic b-cell function and gene expression in the major peripheral organs that control energy flux: white
adipose tissue (WAT), the liver and skeletal muscle, in male offspring 17 and 28 weeks old. Pregnant mice were treated with
a subcutaneous injection of 10 mg/kg/day of BPA or a vehicle from day 9 to 16 of pregnancy. One month old offspring were
divided into four different groups: vehicle treated mice that ate a normal chow diet (Control group); BPA treated mice that
also ate a normal chow diet (BPA); vehicle treated animals that had a high fat diet (HFD) and BPA treated animals that were
fed HFD (HFD-BPA). The BPA group started to gain weight at 18 weeks old and caught up to the HFD group before week 28.
The BPA group as well as the HFD and HFD-BPA ones presented fasting hyperglycemia, glucose intolerance and high levels
of non-esterified fatty acids (NEFA) in plasma compared with the Control one. Glucose stimulated insulin release was
disrupted, particularly in the HFD-BPA group. In WAT, the mRNA expression of the genes involved in fatty acid metabolism,
Srebpc1, Ppara and Cpt1b was decreased by BPA to the same extent as with the HFD treatment. BPA treatment upregulated
Pparc and Prkaa1 genes in the liver; yet it diminished the expression of Cd36. Hepatic triglyceride levels were increased in all
groups compared to control. In conclusion, male offspring from BPA-treated mothers presented symptoms of diabesity. This
term refers to a form of diabetes which typically develops in later life and is associated with obesity.
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Introduction
Bisphenol-A BPA is a high production volume chemical, which
is widely used in manufacturing polycarbonate plastic and epoxy
resins. Releases of BPA to the environment are higher than 1
million pounds per year (Environmental Protection Agency;
http://www.epa.gov/oppt/existingchemicals/pubs/actionplans/
bpa.html). BPA is found in many dairy products, including food
packaging, i.e: inner lining of cans, baby bottles, thermal paper,
etc. [1]. When polycarbonate plastic is heated or treated with acid
or basic media the ester bonds formed between each BPA
monomer are hydrolyzed and BPA then migrates [2]. Because of
its widespread use, BPA is found in the urine of 93% of US citizens
[3] and its concentrations in urine and blood are as high as 1–
18 nM [4].
Bisphenol-A exerts its actions by interfering with the endocrine
system at different levels, although its role as an estrogen mimic is
the best known one [5]. Using genetically modified mice, it has
been demonstrated that it acts as a potent estrogenic compound
after binding to extranuclear estrogen receptors, ERa and ERb
[6,7,8].
The etiology of type-2 diabetes mellitus (T2DM) is based on the
decreased insulin sensitivity in peripheral tissue together with the
disruption of pancreatic b-cell mass and function. Both genetic
and environmental factors play key roles. Epidemiology has
established robust associations of T2DM with obesity, age,
sedentary life, economic status, ethnicity, smoking and exposure
to endocrine disruptors [9,10]. Exposure to bisphenol-A has been
epidemiologically associated to T2DM, cardiovascular diseases,
insulin resistance and obesity [11,12,13].
Animal studies indicate that exposure to BPA is involved in
developmental alterations of the reproductive tract and nervous
system, the incidence of cancer and also in metabolic disorders
including type-2 diabetes and obesity [10,14,15,16]. The timing of
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exposure is a key factor to obtain different metabolic phenotypes.
In adult animals, the exposure to BPA provokes decreased food
intake, lower body temperature and locomotive activity, glucose
intolerance, insulin resistance and alterations of pancreatic beta
cell function [17,18]. Perinatal exposure elicits increased body
weight, adiposity and alterations in glucose tolerance and insulin
sensitivity [19,20,21,22]. A recent study indicates that the perinatal
exposure of rats to low doses of BPA increases weight gain and
exacerbates the effect of a high fat diet on glucose homeostasis and
b-cell function [20]. In mice, exposure to BPA during pregnancy
induced hyperinsulinaemia, glucose intolerance and insulin
resistance in 6 month old male offspring [23,24].
In our research, pregnant mice were exposed to a vehicle or
BPA 10 mg/kg/day and one month old male offspring were fed
either a normal diet (ND) or a high fat diet (HFD) for 13 or 24
weeks. We then studied body weight change, glucose homeostasis,
glucose stimulated insulin secretion (GSIS) and insulin content as
well as gene expression in active metabolic tissue: white adipose
tissue, liver and skeletal muscle.
Materials and Methods
Animals and treatment
Pregnant OF-1 mice were purchased from Charles River
(Barcelona, Spain) and individually housed under standard
conditions. Mice were maintained on 2014 Teklad Global 14%
Protein Rodent Maintenance Diet (Harlan Laboratories, Barce-
lona, Spain), which does not contain alfalfa or soybean meal (chow
diet). The composition of the diet is as follows: calories from
protein, 18%; calories from fat, 11%; and calories from
carbohydrate, 71%, with energy of 2.9 kcal/g.
The ethical committee of Miguel Hernandez University
‘‘Comisio´n de E´tica en la Investigacio´n Experimental’’ specifically
reviewed and approved this study (approval ID: IB-AN-001-11).
Animals were treated humanely and with regard to alleviate
suffering.
BPA was dissolved in tocopherol-stripped corn oil and
administered subcutaneously on days 9–16 of gestation. The daily
dose used was 10 mg/kg. Pups of the same treatment group were
pooled together and then placed in equal numbers with foster
mothers of the same treatment group. Animals were weaned on
postnatal day 21 and housed (8 mice/group) from weaning
through adulthood in type III cage of polycarbonate plastic
(Tecniplast), 530 cm2. We used new cages to avoid BPA release as
much as possible. Pups housed together were of the same sex. After
the age of one month, they were maintained, ad libitum, during 13
or 24 weeks on a chow diet or High Fat Diet (HFD), D12451,
(Research Diets Inc., New Brunswick, NJ, USA.). Experiments
were performed when mice were 17 or 28 weeks of age. The
composition of the diet is as follows: calories from protein, 20%;
calories from fat, 45%, and calories from carbohydrate, 35%, with
energy of 4.7 kcal/g. We should consider that, minor differences
in the composition exist between a chow diet and the
corresponding control low-fat diet for the HFD. Composition of
diets may determine changes in gene expression, however,
differences between chow diet and HFD or control low-fat diet
and HFD are low.
Only male offspring was used in this study since previous work
from our group demonstrated that under the same BPA treatment
no differences on glucose homeostasis were found in the female
offspring, at least during the analyzed period of life.
Islet cell isolation
Pancreatic islets of Langerhans were isolated by collagenase
(Sigma, Madrid, Spain) digestion (modified from [25]). The
solution used for the isolation of the islets of Langerhans contained
(in mmol/l): 115 NaCl, 10 NaHCO3, 5 KCl, 1.1 MgCl2, 1.2
NaH2PO4, 2.5 CaCl2, 25 HEPES, and 5 D-glucose, pH 7.4, as
well as 0.25% BSA. Freshly isolated islets were used for calcium
and insulin secretion measurements after 2 hours of recovery.
Glucose and insulin tolerance tests
For intraperitoneal glucose tolerance tests (ipGTT), animals
were fasted for 6 h [26], and blood samples were obtained from
the tail vein. Animals were then injected intraperitoneally with
1.5 g/kg body weight of glucose, and blood samples were taken at
the indicated intervals.
For intraperitoneal insulin tolerance tests (ipITT), fed animals
were used. Animals were injected intraperitoneally with 0.75 IU/
kg body weight of soluble insulin, and blood samples were
obtained from the tail vein. Blood glucose was measured in each
sample using an Accu-check compact glucometer (Roche, Madrid,
Spain). Levels of glycemia after insulin injection are expressed as
% of glycemia compared to basal glycemia levels in fed state.
ipGTT and ipITT were made at 17 and 28 weeks of age.
Serum analysis
Blood samples were collected for biochemical analysis at
decapitation in fed state animals. Serum samples were obtained
by centrifugation for 15 minutes at 1200 rpm at 4uC. Samples
were stored at 280uC. The serum insulin level was analyzed by
Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem, Downers
Grove, IL). Serum glycerol and triglyceride levels were measured
by Serum Triglyceride Determination kit (TR0100, Sigma). Non-
esterified fatty acids (NEFAs) were measured using a NEFA-HR(2)
kit for serum determination (Wako).
Insulin secretion and content
Freshly isolated islets were left to recover in the isolation
medium for 2 h in the incubator at 37uC. After recovery, groups of
5 were transferred to 400 ml of a buffer solution containing
140 mM NaCl, 4.5 mM KCl, 2.5 mM CaCl2, 1 mM MgCl2,
20 mM HEPES and the corresponding glucose concentration (3, 8
or 16 mM) with final pH at 7.4. Afterwards, 100 ml of the buffer
solution with the corresponding glucose concentration with 5%
BSA was added, incubated at room temperature for 3 min and left
to cool down for 15 min on ice. Then, the medium was collected
and insulin was measured in duplicate samples by radioimmuno-
assay using a Coat-a-Count kit (Siemens, Los Angeles, CA, USA).
Protein concentration was measured by the Bradford dye method
[27].
To obtain the insulin content, the islets grouped in batches of 5
were handpicked with a micropipette and incubated overnight in
an ethanol/HCl buffer (75% Ethanol (v/v); 0.4% HCl (stock 37%)
(v/v) and 24.6% distilled water (
v/v)) at 4uC. At the end of the
incubation period, the buffer was removed and studied for insulin
content using radioimmunoassay with a Coat-a-Count kit. Protein
determination was performed using the Bradford dye method.
Insulin and protein content was determined in each islet sample
and the ratio of both parameters was calculated for each sample.
Real-time PCR
Quantitative PCR assays were performed using CFX96 Real
Time System (Bio-Rad, Hercules, CA) and 7500 Real Time PCR
System (Applied Biosystems, Foster City, CA). RNA extraction
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was made with TriPure Isolation Reagent (Roche), and 1 mg of
RNA was used for retrotranscription reaction (HighCapacity
cDNA Reverse transcription, Applied Biosystems). Reactions were
carried out in a final volume of 10 ml, containing 200 nM of each
primer, 1 ml of cDNA, and 16IQ SYBR Green Supermix (Bio-
Rad). Samples were subjected to the following conditions: 10 min
at 95uC, 40 cycles (10 s at 95uC, 7 s at 60uC, and 12 s at 72uC),
and a melting curve of 63–95uC with a slope of 0.1 C/s. The
housekeeping gene was ribosomal protein large P0, also known as
36B4, and it was used as the endogenous control for quantification
[28]. The resulting values were analyzed with CFX Manager
Version 1.6 (Bio-Rad), and values were expressed as the relative
expression respect to control levels (22DDCT) [29]. Primers are
described in Table S1.
Triglycerides extraction and quantification in liver
Liver tissue (100 mg) was homogenized and then added 500 mL
of SDS 0.1% in an eppendorf tube. The mixture was homoge-
nized again and was left shaking overnight at room temperature.
Then 400 mL of the mix were transferred to a new tube, a volume
of methanol was added and the sample was mixed. After that,
800 mL of chloroform were added and the mixture was incubated
during 30 min on ice. Then 48 mL of KCl 0.5 M were added and
the mixture was incubated during 30 min on ice. The sample was
then centrifuged for 10 min at 2000 rpm at 4uC. The organic
phase was transferred to an eppendorf tube and the chloroform
was let to evaporate overnight. Finally the extract was resuspended
with 100% Ethanol and triglycerides were measured by using the
Triglyceride Determination kit (TR0100, Sigma).
Recording intracellular calcium concentrations
Freshly isolated islets of Langerhans were loaded with 5 mM
Fura-2 AM for at least 1 h at room temperature. Calcium
recordings in islets were obtained by imaging intracellular calcium
under an inverted epifluorescence microscope (Zeiss, Axiovert
200). Images were acquired every 2 s with an extended
Hamamatsu Digital Camera C4742-95 (Hamamatsu Photonics,
Barcelona, Spain) using a dual filter wheel (Sutter Instrument CO,
CA, USA) equipped with 340 nm and 380 nm, 10 nm bandpass
filters (Omega optics, Madrid, Spain). Data was acquired using
Aquacosmos software from Hamamatsu (Hamamatsu Photonics,
Barcelona, Spain). Fluorescence changes are expressed as the ratio
of fluorescence at 340 nm and 380 nm (F340/F380). Results were
plotted and analyzed using commercially available software
(Sigmaplot, Jandel Scientific).
Statistical analysis
SigmaStat 3.1 software (Systat Software, Inc., Chicago, IL,
USA) was used for all statistical analyses. To assess differences
between treatment groups for each exposure paradigm, we used
the one-way analysis of variance (ANOVA) followed by the Holm-
Sidak or Tukey method. When data did not pass the parametric
test, we used ANOVA on ranks followed by Dunn’s test. Results
were considered significant at p,0.05. Data are shown as mean 6
SEM.
Results
The effects of BPA on weight, food intake,
retroperitoneal and gonadal fat pad weight and plasma
NEFA
To examine the effects of BPA on the glucose metabolism of
offspring, we treated pregnant mice with either a vehicle or BPA at
a dose of 10 mg/kg/day on GD9–GD16. Throughout the groups,
animals were matched for gestation day to minimize potential
differences in the background levels of maternal hormones during
the last phase of pregnancy. One month old mice were exposed to
a normal chow diet (ND) or a high fat diet (HFD) for 13 weeks or
24 weeks. In total, we had 4 different groups for each age: vehicle
treated animals fed ND (Control), animals exposed to 10 mg/kg/
day of BPA fed ND (BPA), vehicle treated animals fed a HFD
(HFD) and animals exposed to 10 mg/kg/day of BPA fed a HFD
(HFD-BPA).
Body weights (BWs) at birth was diminished in BPA-treated
mice (data not shown). BWs from the different groups were
measured weekly starting at the age of 4 weeks (Figure 1A). HFD
and HFD-BPA groups presented a higher weight than those fed a
ND during the whole treatment. Remarkably, those in the BPA
group started to gain more weight in the 18th week compared with
the Control and from that point on their weight increased until it
became similar to that of the HFD and HFD-BPA groups
(figure 1A). The weight increase of the BPA group was not
significantly different when compared with the rest of the groups
using ANOVA either at the age of 17 weeks or 28 weeks (Figure 1B
and C). However, at the age of 28 weeks, it was significantly
different when compared with the Control as shown by the use of
student’s t-test (Figure 1C). Calorie intake remained unchanged in
BPA mice compared with the Control group throughout the study
(Figure 1D and E), yet it was increased in HFD and HFD-BPA
groups compared with Control (Figure 1D and E) and remarkably,
in HFD-BPA compared with HFD when they were 28 weeks old
(Figure 1E).
By the age of 17 weeks the HFD animals were observed to have
significant differences in both the perigonadal and retroperitoneal
fat pad weights compared with the rest of the groups. It should be
noted that the HFD-BPA group presented a diminished
perigonadal and retroperitoneal fat pad weight compared with
the HFD one (Figure 2A and B). Later, at the age of 28 weeks,
perigonadal fat pad weight was significantly increased in the BPA
group compared with the Control (Figure 2C). As for the
retroperitoneal fat pad; its weight was increased in the HFD
group compared with the rest of the groups and despite being
higher in the HFD-BPA group than in the Control one, it was
significantly lower compared with the HFD group (Figure 2D). No
significant differences were observed with BPA treatment in the
weight of the liver and gastrocnemius muscle (Figure S1).
Plasma non esterified fatty acid (NEFA) levels were increased in
all groups, BPA, HFD and HFD-BPA compared with the control
group at 17 and 28 weeks old (Figure 2E and F).
Glucose tolerance and insulin sensitivity
In 17-week-old animals, a difference in fasting blood glucose
levels was observed between the control group and the rest of the
groups (table 1 and figure 3A). Remarkably, the BPA group was
hyperglycemic in the fasted state compared with the control while
no significant differences were found between the BPA, HFD and
HFD-BPA groups (Table 1 and Figure 3A). In the fed state, no
significant differences were found in glucose levels and plasma
insulin between the 4 different groups using ANOVA one way
(Table 1). The BPA, HFD and HFD-BPA groups presented higher
insulin levels compared with the control one when each condition
was compared with the control using student’s t-test (p,0.05) and
presented a high tendency when Kruskal-Wallis one way ANOVA
on ranks was used (p,0.1). In 17 week old mice, glucose tolerance
was impaired in the HFD and HFD-BPA groups compared with
the Control, while HFD and HFD-BPA presented no significant
difference (Figure 3A, see inset). The BPA group showed a
Bisphenol-A Provokes Diabesity in Mice
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tendency to be glucose intolerant although no significant
differences were found compared with the Control (Figure 3A,
see inset). When we used an intraperitoneal insulin tolerance test
(ipITT) to study insulin sensitivity, no change was obtained
between the 4 different groups (Figure 3B).
In 28-week-old animals, the BPA group presented hyperglycae-
mia in contrast to the control group (Table 2 and Figure 3C).
Moreover, the AUC of the BPA and HFD groups were
significantly different compared with the control one but presented
no significant difference when compared with each other
(figure 3C, inset). In the fed state, no statistically significant
difference was observed in plasma glucose and insulin levels
(table 2), although a high tendency towards hyperinsulinaemia was
seen in the BPA group. Insulin sensitivity had a tendency to be
impaired in all groups compared with the Control one, yet no
significant differences were obtained during the first 45 minutes
after injecting insulin (Figure 3D). When comparing just Control
and HFD conditions we found statistically significant differences in
the glycemia levels in response to insulin (Figure S3).
The change induced by HFD on glucose tolerance seems to be
more pronounced at 17 than at 28 weeks of age, we believe this
could be related to a deterioration of glucose tolerance in vehicle
treated mice with age.
In summary, these experiments pointed to the fact that animals
treated with BPA had an impaired glucose tolerance when
compared with the Control. Remarkably, the phenotype of the
BPA group resembles that of HFD mice.
Figure 1. Body weight and calorie intake in the four study groups. A) Body weight evolution from 4 weeks to 28 weeks old. Animals were
started on the HFD at 4 weeks. Arrows indicate weeks 17 and 28, the age when experiments were done (n = 150 animals from 26 litters). B) Body
weight of offspring from the four different groups at 17 weeks (Control n = 46 animals from 8 litters, BPA n=28 from 5 litters, HFD n=38 from 8 litters
and HFD-BPA n= 30 from 5 litters). C) Body weight of offspring from the four different groups at 28 weeks (Control n = 19 animals from 8 litters, BPA
n= 15 from 5 litters, HFD n=26 from 8 litters and HFD-BPA n= 15 from 5 litters), *P,0.01 Student’s t-test compared to Control. D) Food intake for the
four different groups compared at 17 weeks old (n = 142 animals from 26 litters) E) Food intake for the four different groups compared at 28 weeks
old (n = 75 animals from 26 litters). Data are expressed as mean6SEM. Significance by one way ANOVA followed by Tukey, Holm-sidak or Dann’s
method, p,0.05. b compares control vs. HFD, c control vs. HFD-BPA, d HFD vs. BPA, e HFD vs. HFD-BPA, f BPA vs. HFD-BPA.
doi:10.1371/journal.pone.0100214.g001
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The effect of BPA on glucose stimulated insulin secretion
(GSIS) and insulin content
Islets from adult offspring whose mothers were treated with BPA
during pregnancy, feeding with either HFD or ND, presented an
increased insulin secretion in response to basal levels of glucose,
3 mM, (Figure 4A inset) as well as in response to stimulatory
glucose levels, 16 mM at 17 weeks old (Figure 4A). HFD treated
animals presented an increase of GSIS similar to that found in the
BPA group, even though basal insulin secretion at 3 mM of
glucose was not increased. The HFD-BPA group showed an
enhanced insulin release in response to 3 and 8 mM of glucose
when compared to the control but a diminished GSIS in response
to 16 mM of glucose when compared with the BPA group, which
suggests that BPA exposure may have a detrimental action on high
glucose stimulated insulin secretion when combined with a HFD.
No difference in insulin secretion between the BPA and Control
groups was obtained in 28-week-old animals, yet the HFD and
HFD-BPA groups showed a significantly diminished GSIS when
compared with the control and BPA groups. Notably, insulin
release in response to 8 and 16 mM of glucose was decreased in
the HFD-BPA group compared with the HFD one (Figure 4B).
This result indicates that GSIS was progressively worsened by
HFD in offspring whose mothers were exposed to BPA during
Figure 2. Adipose tissue weight and plasma NEFA levels in offspring. A) Perigonadal and B) Retroperitoneal fat depots, expressed as % of
body weight at 17 weeks old (n = 8 animals from 5–8 litters). C) Perigonadal and D) Retroperitoneal fat depots, expressed as % of body weight at 28
weeks old. (n = 6–8 animals from 5–8 litters). E) Plasma Nonesterified fatty acids (NEFAs) levels at 17 weeks old (n = 7–9 animals from 7 litters) and F)
28 weeks old (n$5 animals from 4–7 litters). Data are expressed in mean 6SEM; significance p,0.05 by one way ANOVA followed by Holm-Sidak or
Dunnett’s method; a control vs. BPA; b control vs. HFD, c control vs. HFD-BPA, d HFD vs. BPA, e HFD vs. HFD-BPA, f BPA vs. HFD-BPA.
doi:10.1371/journal.pone.0100214.g002
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Figure 3. BPA, HFD and HFD-BPA groups exhibit hyperglycaemia and glucose intolerance. A) ipGTT were performed on the four groups
at 17 weeks old. The inset shows mean6SEM of the ipGTT Area Under the Curve (n$6 animals from $6 litters). B) ipITT in 17 week old animals (n$6
animals from $6 litters) C) ipGTT were performed on the four groups at 28 weeks old. The inset shows mean6SEM of the ipGTT Area Under the
Curve (n$12 animals from $6 litters). D) ipITT in 28 week old animal. (n$11 animals from $6 litters). Data are expressed in mean6SEM. Significance
P,0.05 by one way ANOVA followed by Tukey or Dunnett’s method; a control vs. BPA; b control vs. HFD, c control vs. HFD-BPA, d HFD vs. BPA, e HFD
vs. HFD-BPA, f BPA vs. HFD-BPA.
doi:10.1371/journal.pone.0100214.g003
Table 1. Plasma hormones and metabolite levels in offspring at the age of 17 weeks.
17 Weeks
Control BPA HFD HFD+BPA
Glucose Fasted State (mg/dL) 12166 163613a 19069b 18267c
Glucose (mg/dL) 18968 209613 210614 21866
Insulin (ng/mL) 2.060.3 3.960.6 4.060.9 3.460.5
TG (mg/mL) 0.9860.1 1.1960.3 1.1260.1 0.9860.1
Glycerol (mg/mL) 0.2060.04 0.2360.03 0.3560.04b 0.2860.05
All measurements were performed in the fed state, otherwise stated. Fasting glucose was measured after 6 hours of fasting (n$6 animals from $5 litters). Data are
expressed in mean6SEM. Significance p,0.05 by one way ANOVA followed by Dunnet’s method;
acontrol vs. BPA;
bcontrol vs. HFD,
ccontrol vs. HFD-BPA.
*p,0.05 Students t-test, comparing each condition with Control and p,0.1 using Kruskal-Wallis one way ANOVA on ranks.
doi:10.1371/journal.pone.0100214.t001
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pregnancy and therefore, the effect of HFD was exacerbated by
intra uterine BPA exposure (Figure 4B).
At the age of 17 weeks, islet insulin content was significantly
higher in the BPA and HFD-BPA groups compared with the
Control one, however, the Control and HFD groups did not
present differences (Figure 4C). At the age of 28 weeks, the
situation was different. There were no significant differences
between the Control, BPA and HFD-BPA groups and the HFD
Table 2. Plasma hormones and metabolite levels in 28 week old offspring.
28 Weeks
Control BPA HFD HFD+BPA
Glucose Fasted State (mg/dL) 16367 19365a 16768 155612f
Glucose (mg/dL) 18664 20967 18067d 183612
Insulin (ng/mL) 2.660.4 3.961.3 2.560.8 2.160.7
TG (mg/mL) 1.560.2 1.9360.2 1.360.2 1.0160.1
Glycerol (mg/mL) 0.3660.04 0.3960.03 0.3860.03 0.3660.05
All measurements were performed in the fed state, otherwise stated. Fasting glucose was measured after 6 hours of fasting. (n$5 animals from $5 litters). Data are
expressed in mean6SEM. Significance p,0.05 by one way ANOVA followed by Dunnet’s method;
acontrol vs. BPA;
dHFD vs. BPA,
fBPA vs. HFD-BPA.
doi:10.1371/journal.pone.0100214.t002
Figure 4. Glucose-induced insulin secretion from isolated islets. A) Insulin secretion from islets exposed to 3, 8 and 16 mM glucose for
1 hour, in animals from the four different groups at the age of 17 weeks. (n$9 experiments with 7 animals from 7 litters). The inset shows the insulin
release when islets were exposed to 3 mM of glucose. B) Insulin secretion from islets exposed to 3, 8 and 16 mM of glucose for 1 hour, in animals
from the four different groups at the age of 28 weeks (n$6 experiments with$6 animals from$6 litters). C) Insulin content from isolated islets at the
age of 17 weeks (n$10 experiments with 7 animals from 7 litters). D) Insulin content from isolated islets at 28 weeks (n$8 experiments with $6
animals from $6 litters). Data are expressed in mean6SEM, p,0.05 by one way ANOVA followed by Tukey, Dunnet or Dunn’s method; a control vs.
BPA; b control vs. HFD, c control vs. HFD-BPA, d HFD vs. BPA, e HFD vs. HFD-BPA, f BPA vs. HFD-BPA.
doi:10.1371/journal.pone.0100214.g004
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group presented an insulin content slightly diminished compared
with the Control (Figure 4D).
In order to evaluate if the stimulus-secretion pathway was
altered, glucose induced Ca2+ signaling was monitored. In 17 week
old animals, [Ca2+]i oscillations induced by 8 and 16 mM of
glucose were unaltered in all the measured conditions (Figure S1
A–C). In 28 week old animals fed a ND, the BPA group presented
a higher [Ca2+]i response to 16 mM of glucose (Figure S2) which
was blunted in HFD animals.
The effects of BPA on gene expression in white adipose
tissue, liver and skeletal muscle
White adipose tissue (WAT), the liver and skeletal muscle are
key organs involved in the metabolism of lipids and carbohydrates.
We measured the changes in the expression of several metabolic
genes involved in lipogenesis, fatty acid uptake, fatty acid
oxidation and glucose uptake and metabolism at the age of 17
weeks. This age was chosen because it was just prior to the
moment when weight increases. Therefore, the observed changes
may have been involved in the process of weight increase.
In WAT (perigonadal pad), a significant decrease in Srebp1c
(Figure 5A), Ppara and Cpt1b (Figure 5C) mRNA levels was found
in the BPA group compared with the Control. In the case of
Srebp1c and Ppara, the changes in BPA were equal to those found in
HFD. Acaca and Cd36 expression tended to decrease (Figure 5A
and B) although the results were not statistically significant. Fas
expression was suppressed in the HFD and HFD-BPA groups to
the same extent, which was expected as a consequence of the
decrease in Srebpc1 expression. Remarkably, Fas mRNA expression
was not modified in the BPA group compared with the Control
(Figure 5A). Hexokinase mRNA expression was markedly down
regulated by HFD-BPA compared to Control (Figure 5D).
In the liver, mRNA levels of Pparc were increased in BPA
treated mice, which differed from what was observed in the HFD
and HFD-BPA groups that remained the same as the Control
(Figure 6A). The mRNA expression of Cd36 involved in FA uptake
was significantly decreased in the BPA and HFD-BPA groups
compared with the Control and HFD (Figure 6B). Acacb levels
were highly increased in BPA group; an opposite effect to the one
produced in the HFD and HFD-BPA groups (Figure 6C) yet the
difference was not significant compared with the control. The
relative expression of Prkaa, the AMPK gene, was significantly
increased in the BPA group and showed a tendency to increase in
the HFD and HFD-BPA groups (Figure 6D). Ppara and Pepck
expression, involved in fatty acid oxidation and gluconeogenesis
was not significantly changed by any of the treatments (Figure 6C,
D). In view of these results we measured the hepatic levels of
triglycerides. We found an increase in all groups of animals
compared to control one. This increase was more pronounced in
the HFD group but we also found a significant increment in the
BPA group (Figure 6E).
In skeletal muscle (gastrocnemius), the mRNA levels of the
transcription factor involved in fatty acid oxidation, Ppara and
Acox1b were markedly up regulated by HFD. A tendency to
increase was present in the BPA and HFD-BPA groups although
the difference was not statistically significant. Remarkably, the
increase in Cpt1a induced by HFD was completely abrogated in
the HFD-BPA group (Figure 7A). The levels of hexokinase as well
as those of Cd36 increased significantly only in the HFD group
(Figure 7B). No significant changes were observed in Glut 4 and
AMPK (Figure 7B).
Discussion
The exposure to endocrine disrupters has been unveiled as a risk
factor for type 2 diabetes mellitus. Numerous evidence exists in
animal and epidemiological studies to establish a link between
EDC exposure and T2D [10,30,31,32]. These endocrine dis-
ruptors include persistent organic pollutants, heavy metals and
plastic components such as phthalates and bisphenol-A, among
others that are presently emerging. In addition, other EDCs have
been described as obesogenic, such as tributyltin, triflumizole
[33,34] and DES [35,36].
The present study together with previous observations
[20,23,24,37] have demonstrated that the exposure to low doses
of BPA during pregnancy alters glucose homeostasis in male
offspring. We have demonstrated here that glucose homeostasis
and mRNA expression of genes involved in the glucose and lipid
metabolism in WAT, liver and skeletal muscle are altered by
prenatal exposure to BPA in a similar manner to that of HFD fed
animals unexposed to BPA. Moreover, some important HFD
effects were worsened by BPA exposure.
The body weight of BPA animals reached levels comparable to
those of HFD at 20 weeks. This was unexpected, because previous
work from our group had not registered an increase in weight
using the same treatment (days 9–16 of pregnancy) [23]. The
reason for this difference is unknown. It is possible that the use of
different animals (from the same strain) or small unpredicted
differences in the batches of diet food may have had an influence
on the results. It is of note that at week 17, 2 mice/cage were
removed, so the cage density changed from 8mice/group to 6
mice/group. This is, however, unlikely to affect weight only in the
BPA-treated group, because this change was performed in all
groups including control. In a recent article, a non-monotonic
relationship between BPA exposure during pregnancy and weight
increase in offspring was reported [24]. Only those animals whose
mothers were exposed to BPA 500 mg/kg/day presented a
significant higher weight at the age of 18 weeks. It is plausible
that the difference in the levels of BPA to which fetuses are
exposed may change from one experiment to another and might
be responsible for the variations in weight increase. In any case,
new experiments are required to unequivocally solve the question
of whether exposure during pregnancy is critical to elicit weight
increase later in life. There is more evidence; however, to suggest
that perinatal exposure (during pregnancy and lactation) to BPA,
increases body weight in mice [19,38,39] and rats [20,40].
Therefore, BPA exposure during the lactation period may be
critical to induce obesity later in life [41]. In humans, evidence has
been recently published suggesting an association between urinary
BPA levels in children and obesity [42], yet more studies are
needed to establish a solid link.
Perigonadal fat pad weight increased with BPA at 28 weeks.
Surprisingly in the HFD-BPA group the weight of the perigonadal
fat pad, was decreased at 17 and 28 weeks without a change in the
total body weight. Notably, perigonadal fat mass was increased in
the BPA group, a phenomenon that will be explored in the future.
In all cases, NEFA levels were highly increased at both ages when
compared with the Control. High NEFA levels in plasma are a risk
factor for metabolic syndrome and induce b-cell death
[43,44,45,46]. Fasted glucose levels were also increased to the
same extent at 17 weeks in the BPA, HFD and HFD-BPA groups.
High glucose levels together with high levels of NEFAs, could be
partly responsible not only for the increase in glucose stimulated
insulin secretion (GSIS) in the BPA and HFD groups at 17 weeks
as a compensatory response, but for the subsequent decrease of
GSIS at 28 weeks because of glucolipotoxicity. Interestingly, this
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decrease was clearly potentiated by BPA in the HFD-BPA group,
indicating that BPA may exacerbate the effect of HFD on
pancreatic b-cell function. These different processes have been
described when the compensatory adaptive state progresses to
diabetes in obese individuals [44,47,48,49,50].
BPA exposure during pregnancy predispossed offspring to
develop glucose intolerance when a glucose tolerance test was
performed after 6 h fasting. At 17 weeks of age the group of
animals that have been treated with HFD are already glucose
intolerance, meanwhile BPA showed a clear tendency to that. At
28 weeks of age, BPA mice presented glucose intolerance to the
same extent that HFD group. No difference was obtained between
the HFD and HFD-BPA groups, unlike what was described in rats
in which perinatal exposure to BPA exacerbated the action of
HFD in male offspring [20].
No differences in insulin sensitivity among the groups were
reported, a slightly different result to the one described in Alonso-
Magdalena et al [23]. In that report, animals exposed to 10 mg/
kg/day presented glucose intolerance and insulin resistance while
those exposed to 100 mg/kg/day were glucose intolerant with no
change in insulin sensitivity. These results suggested that BPA
exposure and insulin sensitivity could be related in a non-
monotonic dose dependent manner. Recently, Angle et al [24],
have demonstrated the existence of this non-monotonic relation-
ship using a full range of BPA doses. Insulin sensitivity decreased at
5 and 5000 mg/kg/day of BPA but remained normal at 50, 500
and 50000 mg/kg/day of BPA. Non-monotonic dose responses are
a general phenomenon that occurs with some EDCs, including
BPA [51]. Therefore, fetuses may be exposed to different BPA
levels in blood depending on the mother’s BPA metabolism, on
whether BPA is administered: by injection, gavage or using a
micropipetter among other variables. Small variations in the real
dose of BPA may exist between one experiment and another. This
might be responsible for the differences in insulin sensitivity,
weight changes and other endpoints found in different reports. It is
worth noting, however, that in most of the published studies,
pregnancy and perinatal BPA exposure worsened glucose toler-
ance at any of the concentrations assayed from 5 and 50000 mg/
kg/day [20,23,24,37,52]. Exposure to lower levels 2.5 ng/kg/day
produced no effect on glucose tolerance [53].
When mRNA expression of key genes in WAT, liver and
skeletal muscle was studied, the most significant changes appeared
in WAT and the liver. In WAT, BPA imitated HFD in decreasing
the transcription factor Srebp1c, which is involved in the
regulation of lipid biosynthesis in animal cells and plays an
important role in the regulation of lipogenic enzyme gene
expression [54]. The main lipogenic enzymes controlled by
Srebp1c are acetyl-CoA carboxylase (Acc) and fatty acid synthase
(Fas). Here the mRNAexpression levels of both enzymes were
decreased due to HFD treatment but not because of the exposure
Figure 5. mRNA gene expression associated with A) Lipogenesis, B) Fatty Acid Uptake, C) Fatty Acid Oxidation and D) Glucose
Uptake and Metabolism, in White Adipose Tissue (WAT) from Control (n$5 animals from $5 litters), BPA (n$5 animals from $5
litters), HFD (n$5animals from$5 litters) and HFD-BPA (n$5 animals from$5 litters) dams at 17 weeks old. Animals were treated with
HFD at week 4. Gene expression was assessed by real-time RT-PCR. Data are expressed as mean6SEM and statistical significance was determined
using one way ANOVA followed by Tukey, Duncans or Dunn’s method. Significance p,0.05; a compared control vs. BPA; b control vs. HFD, c control
vs. HFD-BPA, d HFD vs. BPA, e HFD vs. HFD-BPA, f BPA vs. HFD-BPA.
doi:10.1371/journal.pone.0100214.g005
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to BPA. Thus, it seems that an alternative mechanism may exist to
regulate Fas gene expression in the BPA group.
Peroxisome proliferator-activated receptor-a (Ppara) is a dietary
lipid sensor whose activation results in hypolipidemic effects and
mediates the expression of genes promoting fatty acid beta-
oxidation. BPA exposure decreases Ppara expression in WAT to
the same extent as HFD. A decrease in Ppara should result in a
reduced capacity to metabolize long-chain fatty acids, an effect
reported in Ppara KO mice, that contributes to both increased
adipose tissue stores with aging and to the obese phenotype of
these mice [55]. In the present study, the decrease in Ppara occurs
simultaneously with a decrease in carnitine palmitoyltransferase1b
(Cpt1b) mRNA expression, particularly in the BPA group. Cpt1b is
involved in mitochondrial fatty acid uptake and catalyzes the rate-
limiting step of fatty acid oxidation. The transcription of Cpt1 is
regulated by a number of factors, including peroxisome prolif-
erator-activated receptor-a, glucocorticoids, and insulin [56]. Its
decrease in WAT could result in a lower rate of fatty acids delivery
to other peripheral tissues; mainly the liver. Additionally, it could
contribute to an increase in weight. This would explain why BPA
treatment during pregnancy induced a decreased expression in key
genes such as Srebpc1, Ppara and Cpt1b in offspring to the same
extent as HFD during 13 weeks.
Figure 6. mRNA gene expression associated with A) Lipogenesis, B) Fatty Acid and Glucose Uptake, C) Fatty Acid Oxidation and D)
Glucose Metabolism, in the liver from Control (n$5animals from $5 litters), BPA (n$5 animals from $5 litters), HFD (n$5 animals
from $5 litters) and HFD-BPA (n$5 animals from $5 litters) dams at the age of 17 weeks. Animals started to be treated with HFD at the
age of 4 weeks. Gene expression was assessed by real-time RT-PCR. E) Hepatic trygliceride content from Control (n$5animals from $5 litters), BPA
(n$5 animals from $5 litters), HFD (n$5 animals from $5 litters) and HFD-BPA (n$5 animals from $5 litters) dams at the age of 17 weeks. Data are
expressed as mean6SEM and statistical significance was determined using one way ANOVA followed by Tukey or Dunn’s method. Significance p,
0.05; a compares control vs. BPA; b control vs. HFD, c control vs. HFD-BPA, d HFD vs. BPA, e HFD vs. HFD-BPA, f BPA vs. HFD-BPA.
doi:10.1371/journal.pone.0100214.g006
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In the liver, BPA specifically increases Pparc and AMPK
expression and decreases the expression of Cd36. Pparc expression
in the liver is much lower than in skeletal muscle and adipose tissue
[57,58] but it may have a pivotal role because it controls the
expression of genes associated with lipid metabolism. An increase
in PPARc expression by BPA may increase hepatic fat accumu-
lation [57]. Indeed we do observe an increase of triglycerides
content in the liver of BPA animals compared to control group.
The expression of Cd36 was highly decreased by exposure to BPA,
contrary to the lack of its effect in the HFD group. Cd36 is a fatty
acid transport protein whose increased expression in the liver
contributes to dyslipidemia before the onset of type 2 diabetes
[59]. In our study, Cd36 expression decreased in the BPA and
HFD-BPA groups. This might reduce fatty acid uptake and
thereby contribute to the increase in NEFA levels in plasma as is
the case in CD36 KO mice with higher plasma triglyceride and
NEFA levels [60]. AMPK mRNA levels were elevated in the BPA
group. AMPK is a fuel sensor protein that inhibits anabolic
pathways and activates catabolic pathways in the liver. Over
activity of hepatic AMPK has a net effect of increasing fat
oxidation and decreasing the rate of glucose oxidation [61,62].
Because of its favorable global metabolic effects when activated,
the higher expression of AMPK found in the present study may be
a compensating mechanism to counteract the hyperglycaemia
detected in the BPA, HFD and HFD-BPA groups, which probably
is due to an incomplete blockade of liver gluconeogenesis.
In the skeletal muscle, HFD provoked a downregulation of
Ppara and Acox1b gene expression, yet BPA produced no
significant effect by itself.
During the last decade, environmentally relevant concentrations
of Bisphenol-A have been demonstrated to alter pancreatic beta
cell function [6,63,64,65] and liver metabolism [66,67] and to
induce insulin resistance and hyperinsulinaemia in adult mice
[17,18]. Perinatal or pregnancy exposure to BPA elicited weight
increase and adipocity in offspring [20,24,38,39,40]; altered
glucose tolerance [20,23,24,37,52] and insulin sensitivity
[23,24,37]. Our research has demonstrated that exposure to an
environmentally relevant dose of BPA during pregnancy, alters the
expression of important genes involved in lipogenesis and fatty
acid oxidation in adipocytes as well as fatty acid uptake in the liver.
Figure 7. mRNA gene expression associated with A) Fatty Acid Oxidation and B) Fatty Acid and Glucose Uptake and Metabolism, in
Skeletal Muscle from Control (n$5 animals from $5 litters), BPA (n$5 animals from $5 litters), HFD (n$5 animals from $5 litters)
and HFD-BPA (n$5 animals from $5 litters) dams at the age of 17 weeks. Animals started to be treated with HFD at week 4. Gene
expression was assessed by real-time RT-PCR. Data are expressed as mean6SEM and statistical significance was determined using one way ANOVA
followed by Duncan or Dunn’s method. Significance p,0.05; a compared control vs. BPA; b control vs. HFD, c control vs. HFD-BPA, d HFD vs. BPA, e
HFD vs. HFD-BPA, f BPA vs. HFD-BPA.
doi:10.1371/journal.pone.0100214.g007
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These alterations are associated with increased NEFA levels in
plasma which are a risk factor for type 2 diabetes. In fact, animals
exposed to BPA that were fed a HFD during 24 weeks had a
deteriorated GSIS compared to HFD fed animals. Moreover, BPA
treatment worsened the HFD effect on GSIS indicating that
exposure to BPA exacerbates the deleterious action of HFD in the
pancreatic b-cell. Phenotypically, mice treated with BPA presented
higher body weight, fasted hyperglycaemia and altered glucose
tolerance. These parameters were not aggravated by HFD.
Therefore, these mice suffered primary symptoms of diabesity, a
term used to refer to a form of diabetes which typically develops in
later life and is associated with being obese. Whether human
exposure to bisphenol-A is high enough to cause similar actions to
those found in animals is still a matter of debate [68]. In any case,
the dose of BPA used in the present study (10 mg/kg/day), is
clearly below the referenced dose established by the EPA (50 mg/
kg/day) [69]. As regards its potential translation to a reasonable
exposition dose in humans, recent studies have suggested that the
average adult is exposed to concentrations of BPA, in the range of
0.4–1.5 mg BPA/kg BW per day [70,71]. However, after
exhaustively reviewing all available human studies, scientists have
reported that daily intake of BPA should be higher than initially
thought and that, approximately 500 mg/kg/day would be
required to account for the reported levels of BPA in adults
[72]. Human exposure to BPA is variable but it has been
measured in several studies and the central tendency is that
unconjugated levels of BPA in humans are in the 0.3–4.4 ng/mL
range in tissues and fluids in fetuses, children and adults; which
exceed the circulating levels extrapolated from acute exposure
studies in laboratory animals [73].
Above of that we must bear in mind that we are all exposed to a
mixture of endocrine disruptors, including bisphenol-A, phthalates
and persistent organic pollutants, which have been associated to
type 2 diabetes and other metabolic alterations in human
epidemiological studies. These EDCs may have additive effects
in humans [74]. Although this possibility needs further explora-
tion, it makes the exposure to EDC a real threat for metabolic
disorders.
Supporting Information
Figure S1 Liver and gastrocnemius muscle weights. A)
Liver and B) gastrocnemius muscle weight, both expressed as % of
body weight at the age of 17 weeks. (n$6 animals from $5 litters).
C) Liver and D) gastrocnemius muscle weight, both expressed as
% of body weight at 28 weeks. (n$8 animals from$5 litters). Data
are expressed in mean 6SEM, *p,0.05 BPA vs all conditions by
one way ANOVA followed by Dunnett’s method.
(TIF)
Figure S2 Calcium response to increased glucose
concentration in isolated islets of animals exposed to
BPA in uterus. A) [Ca2+]i response of a representative islet of
Langerhans in response to 3, 8 and 16 mM glucose applied for 5,
11 and 11 min, respectively. B) Area under curve (AUC) was done
during 10 min period in 8 mM glucose and C) in 16 mM of
glucose in 17 week old offspring. D) Area under curve (AUC)
during 10 min period in 8 mM of glucose and E) in 16 mM of
glucose in 28 week old offspring. (n$5 islets from$4 animals from
$4 litters). Data are expressed in mean6SEM and analyzed by
one way ANOVA followed by Holm-Sidak; *p,0.05.
(TIF)
Figure S3 Insulin sensitivity is decreased in HFD
animals compared to control at 28 weeks of age. ipITT
was performed in animals fed with HFD or chow diet during 24
weeks (n$11 animals from $6 litters). Data are expressed in
mean6SEM. Significance P,0.05 by t-test.
(TIF)
Table S1 Real time PCR primers.
(TIF)
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